Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681182 · ClinicalTrials.gov registry record · Phase 4
Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone
A Phase 4 study, sponsored by WakeMed Health and Hospitals.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT05681182 is a Phase 4 study that has completed, run by WakeMed Health and Hospitals. The registered enrollment target is 30 participants.
The verdict
NCT05681182, a Phase 4 study, has completed, sponsored by WakeMed Health and Hospitals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing isolated cardiac arterial bypass grafting (CABG) or valve surgery.
Interventions
- COMBINATION_PRODUCT CardiaMend with the Addition of Amiodarone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05681182
The ClinicalTrials.gov registry entry for NCT05681182 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is WakeMed Health and Hospitals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardiaMend with the Addition of Amiodarone is the first listed.
NCT05681182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05681182 about?
NCT05681182 is a clinical study titled "Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone". The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing isolated cardiac arterial bypass grafting (CABG) or valve surgery.
What is the current status of trial NCT05681182?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-01-20. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT05681182?
The interventions under investigation include: CardiaMend with the Addition of Amiodarone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05681182?
This trial is sponsored by WakeMed Health and Hospitals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.